Director, Regulatory CMC

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, which may be a promising option for patients with cancer. Overview The Director, Regulatory CMC, is responsible for leading one or more drug development programs, with specific emphasis on global regulatory strategy, regulatory submissions, and interaction with global regulatory authorities. The individual must have a good understanding of clinical development strategies and health authority expectations for novel and complex onc